Metabolomics of exhaled breath in critically ill COVID-19 patients: A pilot study
Résumé
Background
Early diagnosis of coronavirus disease 2019 (COVID-19) is of the utmost importance but remains challenging. The objective of the current study was to characterize exhaled breath from mechanically ventilated adults with COVID-19.
Methods
In this prospective observational study, we used real-time, online, proton transfer reaction time-of-flight mass spectrometry to perform a metabolomic analysis of expired air from adults undergoing invasive mechanical ventilation in the intensive care unit due to severe COVID-19 or non-COVID-19 acute respiratory distress syndrome (ARDS).
Findings
Between March 25th and June 25th, 2020, we included 40 patients with ARDS, of whom 28 had proven COVID-19. In a multivariate analysis, we identified a characteristic breathprint for COVID-19. We could differentiate between COVID-19 and non-COVID-19 ARDS with accuracy of 93% (sensitivity: 90%, specificity: 94%, area under the receiver operating characteristic curve: 0•94-0•98, after cross-validation). The four most prominent volatile compounds in COVID-19 patients were methylpent-2-enal, 2,4-octadiene 1-chloroheptane, and nonanal.
Interpretation
The real-time, non-invasive detection of methylpent-2-enal, 2,4-octadiene 1-chloroheptane, and nonanal in exhaled breath may identify ARDS patients with COVID-19.
Mots clés
COVID-19
Intensive care
Mechanical ventilation
Breath analysis
Metabolomics
Statistical analysis
coronavirus
volatile compound
TOF mass spectrometry
mass spectrometry
spectrum analysis
signal processing
multivariate analysis
acute respiratory distress syndrome
real-time
non-invasive detection
COVID-19
| Origine | Publication financée par une institution |
|---|